Tibotec Therapeutics’ Receives FDA Approval For Intelence Tablets
The FDA has granted traditional approval for Tibotec Therapeutics’ Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Intelence is currently marketed in the US by Tibotec, a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.